Experience

We advised the underwriters on the IPO and Nasdaq listing

We advised the underwriters on the IPO of ADSs

Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 10,592,106 shares of Class A common stock of Seer, Inc. at $19.00 per…

Davis Polk advised the representatives of the several underwriters in connection with the initial public offering of 69,000,000 shares of Class A common stock of Maravai LifeSciences…

Davis Polk advised the representatives of the several underwriters in connection with the $240 million initial public offering of 12,650,000 shares of common stock of Olema Oncology at $19…

Davis Polk advised Signify Health on its acquisition of PatientBlox. The acquisition accelerates Signify’s prospective provider payment capabilities for episodes of care, supporting the…

Davis Polk is advising Novo Nordisk A/S on its $1.8 billion acquisition of Emisphere Technologies Inc. and related Eligen SNAC royalty stream obligations owed to MHR Fund Management LLC,…

Davis Polk advised the representatives of the underwriters in connection with the $345 million initial public offering of 14,375,000 shares of common stock of Atea Pharmaceuticals, Inc.,…

Davis Polk advised Coloplast on its acquisition of Nine Continents Medical, an early stage company pioneering an implantable tibial nerve stimulation treatment for over-active bladder. The…

Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $72 million initial public offering by Biodesix, Inc. The common stock is listed on…